Celldex Therapeutics (CLDX) Non-Current Debt (2010 - 2013)

Celldex Therapeutics' Non-Current Debt history runs 4 years deep, the most recent figure standing at $10.1 million for Q1 2013.

• On a quarterly basis, Non-Current Debt rose 2.12% year-over-year to $10.1 million in Q1 2013; TTM through Mar 2013 was $10.1 million, a 2.12% increase from a year earlier, with the FY2012 full-year figure at $5.7 million, down 36.21% from the prior year.
• Non-Current Debt improved to $10.1 million in Q1 2013 per CLDX's latest filing, from $5.7 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $15.0 million in Q1 2011 and bottomed at $5.7 million in Q4 2012.
• The 4-year median for Non-Current Debt is $10.0 million (2011), against an average of $10.1 million.
• Biggest YoY gain for Non-Current Debt was 38.06% in 2012; the steepest drop was 36.21% in 2012.
• Year by year, Non-Current Debt stood at $8.9 million in 2010, then advanced by 1.34% to $9.0 million in 2011, then sank by 36.21% to $5.7 million in 2012, then soared by 75.77% to $10.1 million in 2013.
• Per Business Quant, the three latest CLDX Non-Current Debt figures stand at $10.1 million (Q1 2013), $5.7 million (Q4 2012), and $7.3 million (Q3 2012).